Back to top
more

AMN Healthcare Services (AMN)

(Real Time Quote from BATS)

$43.15 USD

43.15
181,088

+0.52 (1.22%)

Updated Sep 27, 2024 11:54 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (164 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Abiomed (ABMD) Posts Impellas Positive Study Results in Japan

by Zacks Equity Research

Abiomed's (ABMD) latest multi-center, multi-society study of Impella-supported patients is expected to significantly improve patient outcomes.

3 Reasons to Retain PacBio (PACB) Stock in Your Portfolio

by Zacks Equity Research

PacBio's (PACB) strength in its Sequel system raises optimism about the stock.

Moumita C. Chattopadhyay headshot

4 Stocks With Rising Cash Flows to Survive Market Volatility

by Moumita C. Chattopadhyay

Cash indicates a company's true financial health. It holds the key for its existence, development and success and so AMN, WIRE, TGLS and SP are worth buying.

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vinci Surgical System. Higher production costs are a woe.

Quest Diagnostics (DGX) to Offer Lab Services for Lee Health

by Zacks Equity Research

Quest Diagnostics (DGX) inked a new agreement to deliver high-quality diagnostics services for a renowned healthcare provider in Southwest Florida.

Here's Why You Should Retain Boston Scientific (BSX) For Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific's (BSX) impressive top-line results and notable acquisitions.

Inari Medical (NARI) Posts Positive Results of FLASH Registry

by Zacks Equity Research

Inari Medical's (NARI) FlowTriever's latest favorable results are expected to significantly improve the treatment of PE.

Neogen (NEOG) Launches Test for Detection of Cashew Allergen

by Zacks Equity Research

Neogen's (NEOG) new quantitative test shows a high level of specificity to very low levels of cashew protein (down to 0.2 ppm).

Exact Sciences (EXAS) Cologuard Business Grows Amid Cost Woes

by Zacks Equity Research

Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is now offering therapy selection tests for patients with advanced cancer.

QIAGEN (QGEN) Assays to Detect Organ Transplant-Related Viruses

by Zacks Equity Research

QIAGEN's (QGEN) latest additions to the NeuMoDx assay menu will help identify EBV and HHV-6 viruses in immunocompromised patients.

3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.

Teleflex (TFX) Witnesses Lower UroLift Sales, Cost Woes

by Zacks Equity Research

Teleflex's (TFX) lowered revenue and adjusted EPS outlook for 2022 indicates lackluster performance, which increases investors' concern.

Abiomed's (ABMD) Impella-Related Research Gets FDA Clearance

by Zacks Equity Research

Abiomed's (ABMD) latest regulatory clearances for clinical research of Impella heart pumps in AMI cardiogenic shock patients are expected to significantly improve patient outcomes.

3 Reasons to Hold Catalent (CTLT) Stock in Your Portfolio

by Zacks Equity Research

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism about the stock.

Cigna's (CI) Arm Adds Five Digital Health Apps to Its Platform

by Zacks Equity Research

Cigna's (CI) unit bolsters its clinical platform Digital Health Formulary by including five on-line solutions, aiming to relieve people from chronic medical conditions.

3 Reasons to Hold Insulet (PODD) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Insulet (PODD) on Omnipod's continued market access expansion.

Here's Why Investors Should Retain Integra (IART) Stock for Now

by Zacks Equity Research

Investors are optimistic about Integra's (IART) better-than-expected results and the continued demand for its products.

Tandem Diabetes (TNDM) Faces Expense Woes, Macro Issues

by Zacks Equity Research

Factoring in the pandemic and competitive pressure as well as evolving economic environment, including inflation and the threat of recession, Tandem Diabetes (TNDM) slashes full-year guidance.

Wall Street Analysts Believe AMN Healthcare (AMN) Could Rally 35%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 34.7% in AMN Healthcare (AMN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

AMN Healthcare Services (AMN) Stock Moves -0.55%: What You Should Know

by Zacks Equity Research

In the latest trading session, AMN Healthcare Services (AMN) closed at $106.05, marking a -0.55% move from the previous day.

LHC Group's (LHCG) Latest Tie-Up to Improve Patient Services

by Zacks Equity Research

LHC Group's (LHCG) latest JV is expected to expand the availability of vital healthcare services to patients in the comfort of their homes.

Here's Why Investors Should Retain Globus Medical (GMED) For Now

by Zacks Equity Research

Investors are optimistic about Globus Medical's (GMED) better-than-expected results and new product introductions.

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain from solid product portfolio despite forex woes.

CVS Health (CVS) Progresses With Safe Medication Approach

by Zacks Equity Research

A major feature of CVS Health's (CVS) time delay safe function is that it cannot be overridden and is designed to deter pharmacy robbers.

Here's Why You Should Retain Patterson Companies (PDCO) Stock

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.